These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 37251333)

  • 1. Research progress of interleukin-15 in cancer immunotherapy.
    Cai M; Huang X; Huang X; Ju D; Zhu YZ; Ye L
    Front Pharmacol; 2023; 14():1184703. PubMed ID: 37251333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potential of interleukin-21 in cancer.
    Isvoranu G; Chiritoiu-Butnaru M
    Front Immunol; 2024; 15():1369743. PubMed ID: 38638431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy.
    Wang C; Kong L; Kim S; Lee S; Oh S; Jo S; Jang I; Kim TD
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic gene modified cell based cancer vaccines.
    Kozłowska A; Mackiewicz J; Mackiewicz A
    Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 21 treatment in a murine model as a novel potential cytokine immunotherapy for colon cancer.
    Chen C; Liu X; Ren Y
    Adv Clin Exp Med; 2018 May; 27(5):583-589. PubMed ID: 29616746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The IL-2 cytokine family in cancer immunotherapy.
    Sim GC; Radvanyi L
    Cytokine Growth Factor Rev; 2014 Aug; 25(4):377-90. PubMed ID: 25200249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
    Tahara H; Lotze MT
    Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-cancer Therapies Employing IL-2 Cytokine Tumor Targeting: Contribution of Innate, Adaptive and Immunosuppressive Cells in the Anti-tumor Efficacy.
    Mortara L; Balza E; Bruno A; Poggi A; Orecchia P; Carnemolla B
    Front Immunol; 2018; 9():2905. PubMed ID: 30619269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALKS 4230: a novel engineered IL-2 fusion protein with an improved cellular selectivity profile for cancer immunotherapy.
    Lopes JE; Fisher JL; Flick HL; Wang C; Sun L; Ernstoff MS; Alvarez JC; Losey HC
    J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32317293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Uppendahl LD; Felices M; Bendzick L; Ryan C; Kodal B; Hinderlie P; Boylan KLM; Skubitz APN; Miller JS; Geller MA
    Gynecol Oncol; 2019 Apr; 153(1):149-157. PubMed ID: 30658847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Stimulation with Interleukin-18 and Interleukin-12 Potently Induces Interleukin-8 Production by Natural Killer Cells.
    Poznanski SM; Lee AJ; Nham T; Lusty E; Larché MJ; Lee DA; Ashkar AA
    J Innate Immun; 2017; 9(5):511-525. PubMed ID: 28633138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
    Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin 15 in Cell-Based Cancer Immunotherapy.
    Zhou Y; Husman T; Cen X; Tsao T; Brown J; Bajpai A; Li M; Zhou K; Yang L
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP.
    Fabbi M; Carbotti G; Ferrini S
    J Leukoc Biol; 2015 Apr; 97(4):665-75. PubMed ID: 25548255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy.
    Weber R; Groth C; Lasser S; Arkhypov I; Petrova V; Altevogt P; Utikal J; Umansky V
    Cell Immunol; 2021 Jan; 359():104254. PubMed ID: 33296753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting interleukin-10 signalling for cancer immunotherapy, a promising and complicated task.
    Ni G; Zhang L; Yang X; Li H; Ma B; Walton S; Wu X; Yuan J; Wang T; Liu X
    Hum Vaccin Immunother; 2020 Oct; 16(10):2328-2332. PubMed ID: 32159421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Culturing the Human Natural Killer Cell Line NK-92 in Interleukin-2 and Interleukin-15 - Implications for Clinical Trials.
    Törnroos H; Hägerstrand H; Lindqvist C
    Anticancer Res; 2019 Jan; 39(1):107-112. PubMed ID: 30591446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives.
    Xu H; Shi M; Shao C; Li H; Wu J; Yu Y; Fang F; Guo Y; Xiao W
    Microb Cell Fact; 2021 Jun; 20(1):115. PubMed ID: 34107983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine regulation of natural killer cell effector functions.
    Zwirner NW; Domaica CI
    Biofactors; 2010; 36(4):274-88. PubMed ID: 20623510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.